Summary
Piroxicam (20 mg once daily) was administered orally to six healthy young volunteers for 15 days. Trough steady-state levels of piroxicam and 5′-hydroxypiroxicam were 5.5 and 1.2 µg/ml, respectively. Piroxicam's plasma half-life (54.9 h) was significantly shorter than that of 5′-hydroxypiroxicam (70.5 h). Percent unbound piroxicam and 5′-hydroxypiroxicam in plasma at steady-state averaged 1.10 and 8.07 respectively. An average of 25.2% of the dose was recovered in urine as 5′-hydroxypiroxicam; approximately two-thirds (17.2%) in the form of the glucuronide conjugate. Average steady-state plasma levels (Css) of piroxicam (7.0 µg/ml) were significantly higher than predicted from a previously reported single dose study (5.3 µg/ml).
This is a preview of subscription content, log in via an institution to check access.
References
Brogden RN, Heel RC, Speight TM, Avery GS (1984) Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 28: 292–323
Darragh A, Gordon AJ, O'Byrne H, Hobbs D, Casey E (1985) Single-dose and steady-state pharmacokinetics of piroxicam in elderly vs young adults. Eur J Clin Pharmacol 28: 305–309
Fourtillan J-B, Dubourg D (1984) Pharmacokinetics of piroxicam with multiple dosing. Comparison between two dosage regimens. R Soc Med Int Congr Symp Ser 67: 77–81
Hobbs DC, Twomey TM (1979) Piroxicam pharmacokinetics in man: Aspirin and antacid interaction studies. J Clin Pharmacol 19: 270–281
Lombardino JG (1981) Synthesis and anti-inflammatory activity of metabolites of piroxicam. J Med Chem 24: 39–42
Nuotio P, Makisara P (1978) Pharmacokinetic and clinical study of piroxicam. R Soc Med Int Congr Symp Ser 1: 25–30
Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK (1985) Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 37: 13–18
Richardson CJ, Ross SG, Blocka KLN, Verbeeck RK (1986) High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5′-hydroxypiroxicam in human plasma and urine. J Chromatogr 382: 382–388
Rogers HJ, Spector RG, Morrison PJ, Bradbrook ID (1981) Comparative steady-state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects. Eur J Rheumatol Inflamm 4: 303–308
Twomey TM, Hobbs DC (1978) Biotransformation of piroxicam by man. Fed Proc 37: 271
Verbeeck RK, Blackburn JL, Loewen GR (1983) Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 8: 297–331
Verbeeck RK, Richardson CJ, Blocka KLN (1986) Clinical pharmacokinetics of piroxicam. J Rheumatol 13: 789–796
Wiseman EH, Boyle JA (1980) Piroxicam (Feldene). Clin Rheum Dis 6: 583–613
Wiseman EH, Hobbs DC (1982) Review of pharmacokinetic studies with piroxicam. Am J Med 72: 9–17.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Richardson, C.J., Blocka, K.L.N., Ross, S.G. et al. Piroxicam and 5’-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 32, 89–91 (1987). https://doi.org/10.1007/BF00609964
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609964